Case Reports in Endocrinology

Case Reports in Endocrinology / 2015 / Article

Case Report | Open Access

Volume 2015 |Article ID 606389 | 6 pages | https://doi.org/10.1155/2015/606389

Calcitonin-Secreting Neuroendocrine Carcinoma of Larynx with Metastasis to Thyroid

Academic Editor: Osamu Isozaki
Received10 Jul 2015
Revised04 Sep 2015
Accepted07 Sep 2015
Published28 Sep 2015

Abstract

Primary neuroendocrine tumors of the larynx are rare, with moderately differentiated neuroendocrine carcinoma (MDNC) being the most frequent histologic type. We report a MDNC in a 57-year-old gentleman with an enlarging right-sided neck mass. Flexible fiberoptic exam revealed a right arytenoid lesion. Histology from excisional biopsy was concerning for medullary thyroid carcinoma (MTC) versus NET of the larynx. Immunohistochemistry was diffusely positive for calcitonin and CEA and focally positive for TTF-1. Serum calcitonin was elevated. Thyroid ultrasound was unremarkable. The patient underwent laryngectomy, thyroidectomy, and neck dissection. Pathology showed neuroendocrine carcinoma of right arytenoid with positive cervical lymph nodes. A 4 mm deposit of NET was present in right thyroid with adjacent intravascular tumor consistent with thyroidal metastasis from a primary laryngeal NET (MDNC). MDNC and MTC can be microscopically indistinguishable. Both tumors can stain positively for calcitonin and CEA. TTF-1 staining has been useful to help distinguish these tumors as it is strongly and diffusely positive in MTC, but usually negative (or only focally positive) in MDNC. We report the fourth case of primary neuroendocrine carcinoma of the larynx associated with elevated serum calcitonin level and the first such case associated with metastasis to the thyroid.

1. Introduction

Neuroendocrine tumors of the larynx are rare, accounting for ~0.6% of laryngeal neoplasms [1]. Four types of neuroendocrine tumors of the larynx have been identified by the WHO: well-differentiated neuroendocrine carcinoma (typical carcinoid), moderately differentiated neuroendocrine carcinoma (atypical carcinoid), poorly differentiated neuroendocrine carcinoma (small cell carcinoma, neuroendocrine type), and paraganglioma [2]. Moderately differentiated neuroendocrine carcinoma (MDNC) is the most frequent type of all neuroendocrine tumors of the larynx [2, 3].

MDNC of the larynx and medullary thyroid carcinoma (MTC) demonstrate similar morphological features and can be microscopically indistinguishable, particularly when presenting as metastasis [4]. Both tumors stain positively for calcitonin and CEA. TTF-1 staining has been useful to help distinguish these tumors as it is strongly and diffusely positive in medullary thyroid carcinoma, but usually negative (or only focally positive) in MDNC [2, 4]. To the best of our knowledge, only 3 cases of neuroendocrine carcinoma of the larynx with elevated serum calcitonin have been reported [57]. We report the fourth case of primary calcitonin-producing neuroendocrine tumor of the larynx. There are <20 cases of neuroendocrine tumors metastasizing to the thyroid [810]. This is the first case reported of a neuroendocrine tumor of larynx with suspected metastasis to the thyroid.

2. Case Presentation

A 57-year-old gentleman presented with 1-year history of an enlarging right-sided neck mass. The patient noted significant pain/tenderness around the mass with associated right-sided otalgia, odynophagia, and hoarseness. He was a former smoker and alcoholic with no other significant past medical history. There was no family history of cancer or endocrinopathy. Physical exam was remarkable for a 2.5 cm × 1.5 cm mass palpable in the right side of his neck. Flexible fiberoptic exam of the larynx showed a right medial arytenoid lesion of approximately 1 cm in size, mucosally covered with central ulceration. The patient underwent FNA of the palpable right neck mass. Initial pathology was concerning for metastatic carcinoma, favoring poorly differentiated adenocarcinoma of likely primary lung origin. Both PET scan and CT thorax failed to reveal significant lung pathology but rather redemonstrated the laryngeal lesion. The patient then underwent microlaryngoscopy with excisional biopsy of the right arytenoid mass en bloc with the superior aspect of the arytenoid cartilage. Immunohistochemistry was diffusely positive for calcitonin, polyclonal CEA, synaptophysin, chromogranin, and cytokeratin and focally positive for TTF-1. Pathology was concerning for medullary thyroid carcinoma versus neuroendocrine tumor of the larynx. Serum calcitonin was elevated at 157 pg/mL (ref 0–8 pg/mL). Serum CEA was normal. Thyroid ultrasound revealed no abnormalities of the thyroid. Ki-67 staining was 15%, consistent with a moderately differentiated neuroendocrine carcinoma. The case was discussed at our head and neck tumor board with recommendations for total laryngectomy and bilateral neck dissection given the diagnosis of MDNC with evidence of regional lymph node metastasis but no distant metastasis on PET scan. Total thyroidectomy was also recommended given the remaining question on pathology of MDNC versus MTC. The patient subsequently underwent total laryngectomy, bilateral neck dissection, and total thyroidectomy for suspected neuroendocrine tumor.

Pathology showed calcitonin-positive neuroendocrine carcinoma of right arytenoid with 7 positive cervical lymph nodes (5/5 positive right level IIA, 1/3 positive right level III, and 1/5 positive left level IV). A 4 mm calcitonin-positive deposit of neuroendocrine carcinoma was present in right upper pole of the thyroid with adjacent intravascular tumor consistent with thyroidal metastasis from a primary laryngeal NET (moderately differentiated neuroendocrine tumor). Initial pathology did not report C-cell hyperplasia. However, on re-review of the images, it was felt that the calcitonin stain was less than ideal. Repeat staining was conducted and it is believed that there may be bilateral C-cell hyperplasia in the thyroid in addition to the tumor focus. RET mutation testing has been requested on one of the large metastatic tumor deposits in the lymph nodes.

While serum calcitonin level remained elevated, it did significantly decrease to 35 pg/mL postoperatively. The patient subsequently underwent adjuvant radiation therapy to the operative site delivered by intensity-modulated radiation therapy (IMRT). At 2-month follow-up, serum calcitonin had increased to 55 pg/mL, but without palpable recurrence on examination. At 6-month follow-up, serum calcitonin level had increased to 320 pg/mL. CEA remained normal. The patient complained of development of multiple subcutaneous nodules on chest, back, and forearm. These nodules were palpable on exam but had no associated overlying skin changes. PET scan showed interval development of multiple FDG avid nodules in subcutaneous tissue corresponding to the palpable nodules. There was no evidence of recurrence in the neck. Fine needle aspiration of one of the subcutaneous nodules was consistent with metastatic neuroendocrine carcinoma (positive for both calcitonin and synaptophysin). The patient was discussed at a multidisciplinary tumor board and it was determined that his disease was incurable given his distant metastasis (M1 stage). He was offered palliative chemotherapy and radiation; however the patient elected for no further treatment and is currently on hospice care.

3. Discussion

Neuroendocrine tumors of the larynx are rare, with just over 500 cases recorded in the literature since initially described by Goldman et al. in 1969 [11]. MDNC is the most common of the neuroendocrine tumors of the larynx [3]. MDNC is the second most common primary laryngeal malignancy following only squamous cell carcinoma. This tumor occurs 2-3 times more commonly in men and usually in heavy smokers. The average age at presentation is 61. Clinically, patients present with hoarseness, dysphagia, throat pain, and/or a neck mass [2]. Over 90% arise in the supraglottic larynx, in vicinity of the aryepiglottic fold, arytenoid, or false vocal cord [2]. Most thyroid carcinomas, on the other hand, invade the subglottis or trachea, sparing the supraglottis [12].

Medullary carcinoma of the thyroid (MCT) is another rare tumor of neuroendocrine origin. It accounts for ~3–5% of all thyroid gland cancers [13]. MTC arises from the C-cells of the thyroid gland which secrete calcitonin. The majority of the cases are sporadic (75%), although approximately 25% of MTC is hereditary due to germline mutation of the RET protooncogene, as seen in multiple endocrine neoplasias (MEN) 2A and 2B [13]. Sporadic MTC most commonly occurs in the 4th and 6th decade of life [14] and is slightly more common in females [13]. The classic presentation is a palpable solitary thyroid nodule. As C-cells are predominately located in the superior portion of the thyroid gland, the majority of MTC localize to the upper third of a lobe [13, 14].

Histologically, MDNC of the larynx and MTC have overlapping features, including epithelioid to spindle cells with moderate amounts of pale eosinophilic cytoplasm, an architectural arrangement in cords, nests, and solid sheets, characteristic nuclei with stippled neuroendocrine-type chromatin, scattered mitoses, and prominent vascular network [4]. Separating MDNC from MTC may be challenging since both tumors also stain positively for synaptophysin, calcitonin, and CEA [2]. TTF-1 has been useful in that it is strongly and diffusely positive in MTC but usually negative or only focally weakly positive in MDNC [2, 4]. Serum CEA is almost universally elevated in MTC. However, it has not been reported to be elevated in MDNC [2, 15]. Serum calcitonin is also almost invariably elevated in MTC. While many neuroendocrine tumors have been reported to secrete calcitonin, including paragangliomas, pheochromocytomas, gastric carcinomas, small cell pulmonary tumors, VIPomas, insulinomas, and enteropancreatic endocrine tumors [16], only 3 prior reports of hypercalcitoninemia have been reported in MDNC of the larynx.

Sweeney et al. [5] reported the first case of a neuroendocrine tumor of the larynx metastatic to cervical lymph nodes with an elevated serum calcitonin in 1981. This was followed by two additional patients reported by Smets et al. [6] and Insabato et al. [7]. In all three, thyroidectomy failed to disclose a primary thyroid neoplasm. Table 1 compares our patient with the previous three.


Sweeney et al. (1981) [6]Smets et al. (1990) [5]Insabato et al. (1993) [7]LaBryer et al. (present study)

Age/sex54-year-old man 55-year-old man69-year-old man 57-year-old man

SymptomatologyHoarsenessHoarseness and dysphagia HoarsenessHoarseness, otalgia, odynophagia

Location of tumorLeft arytenoid,
3 cervical lymph nodes
Epiglottis,
3 submandibular lymph nodes
Right arytenoid,
1 cervical lymph node
Right arytenoid,
7 cervical lymph nodes

ImmunostainingCalcitonin+
CEA+
TTF-1 – no report
Calcitonin+
CEA+
TTF-1 – no report
Cytokeratin+ 
Chromogranin A+
NSE+
Calcitonin+
CEA – no report
TTF-1 – no report
Cytokeratin+
Chromogranin A+
NSE+
Calcitonin+
CEA+
TTF-1+ (focally)
Cytokeratin+
Chromogranin A+
NSE – not done

Serum calcitonin1200 ng/L
(ref < 200)
3790 pg/L
(ref < 100)
970 pg/mL
(ref < 300)
157 pg/mL
(ref < 8)

Thyroidectomy specimenNegative for MTCNegative for MTCDiffuse goiter, negative for MTC4 mm focus of tumor with adjacent intravascular tumor

CEA = carcinoembryonic antigen; TTF-1 = thyroid transcription factor-1; NSE = neuron specific enolase; MTC = medullary thyroid carcinoma.

As in the previous three reports, the significantly elevated serum calcitonin level in our patient raised initial concerns for possible medullary thyroid carcinoma despite the supraglottic location of primary tumor. Additionally, in our patient, total thyroidectomy revealed 4 mm focus of tumor within the right lobe of the thyroid. Figure 1 demonstrates H&E and calcitonin stains of tumor bed of laryngectomy and the 4 mm thyroid tumor. However, (1) the relatively small size of the thyroid tumor, (2) location of tumor in right arytenoid region (uncommon for MTC metastasis), (3) predominantly lateral cervical distribution of lymph node involvement (more typical for laryngeal than thyroid primary tumor), (4) extensive lymph-vascular space invasion by tumor present in cervical lymph nodes, and particularly (5) the presence of intravascular tumor adjacent to the right thyroid lobe nodule (Figure 2) were more consistent with the diagnosis of thyroidal metastasis from a primary laryngeal neuroendocrine carcinoma. MTC is associated with amyloid deposition in surrounding tissues. Congo red stains performed on both the thyroid tumor and one of the lymph node metastases were negative for demonstrable amyloid. The degree of calcitonin elevation in MTC correlates well with tumor volume [17]. Given our patient’s tumor mass, a higher level of calcitonin would be expected for MTC. While more aggressive MTC may secrete less calcitonin, these tumors tend to have significantly elevated CEA levels [17]. Our patient’s normal serum CEA level and focally positive TTF-1 stain are most consistent with MDNC. TTF-1 staining pattern in both the thyroid tumor and laryngeal tumor was similar to weak nuclear staining of tumor cells. This was in contrast to the strong nuclear staining of normal thyroid epithelium (Figure 3). To our knowledge, this is the first report of a laryngeal neuroendocrine tumor metastatic to the thyroid. We must acknowledge that the bilateral C-cell hyperplasia raises the possibility that the metastasis is actually a micro-MTC. RET testing is currently pending. But, autopsy studies have shown that a substantial proportion (up to 33%) of the normal adult population could have C-cell hyperplasia [18, 19].

Cutaneous metastatic carcinoma is a rare clinical finding. The overall incidence of cutaneous metastases for all types of carcinomas has been estimated to be 5.3% [20]. Skin metastasis of MTC is very rare, with only 16 cases reported in English literature to date [21, 22]. These metastases usually present as flesh-colored nodules that are tender and most commonly located on the scalp. However, laryngeal neuroendocrine tumors are known to metastasize to the skin and subcutaneous tissue. In a review by Woodruff and Senie of 127 published cases of laryngeal MDNC, 22% had metastasis to the skin or subcutaneous sites [23]. Thus, the skin involvement is another factor favoring a diagnosis of MDNC of the larynx. Table 2 recaps the features favoring and disfavoring the diagnosis of MDNC of the larynx with metastasis to the thyroid.


Features favoring diagnosis of MDNC of larynxFeatures disfavoring MDNC of larynx

Age & sexBilateral C-cell hyperplasia of thyroid
Smoking history
Clinical presentation of neck mass, hoarseness, and odynophagia
Supraglottic location of primary tumor
Normal serum CEA
Serum calcitonin level compared to tumor volume
Bilateral lateral cervical lymph node involvement
Extensive lymph-vascular space invasion by tumor in lymph nodes
Only focally positive TTF-1 staining in primary tumor and thyroid tumor
Subcutaneous nodule metastases without overlying skin changes
Negative amyloid stains of thyroid tumor and lymph node metastasis

RET mutation testing pending.

In conclusion, the differential diagnosis in a patient with head/neck cancer and hypercalcitoninemia must include not only medullary thyroid cancer, but neuroendocrine tumors as well. Due to significant overlap in features, even pathological diagnosis may be difficult. Serum CEA levels and staining pattern for TTF-1 may be useful in distinguishing these two tumor types. While skin metastases are rare, this complication is more likely to occur in MDNC than MTC.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. G. Giordano, L. Corcione, D. Giordano, T. D'Adda, L. Gnetti, and T. Ferri, “Primary moderately differentiated neuroendocrine carcinoma (atypical carcinoid) of the larynx: a case report with immunohistochemical and molecular study,” Auris Nasus Larynx, vol. 36, no. 2, pp. 228–231, 2009. View at: Publisher Site | Google Scholar
  2. L. Barnes, J. W. Eveson, P. Reichart, and D. Sidransky, Eds., World Health Organization Classification of Tumours, Pathology and Genetics of Head and Neck Tumours, IARC Press, Lyon, France, 2005.
  3. A. Gillenwater, J. Lewin, D. Roberts, and A. El-Naggar, “Moderately differentiated neuroendocrine carcinoma (atypical carcinoid) of the larynx: a clinically aggressive tumor,” Laryngoscope, vol. 115, no. 7, pp. 1191–1195, 2005. View at: Publisher Site | Google Scholar
  4. M. S. Hirsch, W. C. Faquin, and J. F. Krane, “Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid,” Modern Pathology, vol. 17, no. 6, pp. 631–636, 2004. View at: Publisher Site | Google Scholar
  5. G. Smets, F. Warson, M.-F. Dehou et al., “Metastasizing neuroendocrine carcinoma of the larynx with calcitonin and somatostatin secretion and CEA production, resembling medullary thyroid carcinoma,” Virchows Archiv A Pathological Anatomy and Histopathology, vol. 416, no. 6, pp. 539–543, 1990. View at: Publisher Site | Google Scholar
  6. E. C. Sweeney, L. McDonnell, and C. O'Brien, “Medullary carcinoma of the thyroid presenting as tumors of the pharynx and larynx,” Histopathology, vol. 5, no. 3, pp. 263–275, 1981. View at: Publisher Site | Google Scholar
  7. L. Insabato, G. de Rosa, L. M. Terracciano, G. Lupoli, D. Montedoro, and C. Ravetto, “A calcitonin-producing neuroendocrine tumor of the larynx: a case report,” Tumori, vol. 79, no. 3, pp. 227–230, 1993. View at: Google Scholar
  8. E. Sivrikoz, N. C. Ozbey, B. Kaya et al., “Neuroendocrine tumors presenting with thyroid gland metastasis: a case series,” Journal of Medical Case Reports, vol. 6, article 73, 2012. View at: Publisher Site | Google Scholar
  9. N. Tsoukalas, M. Zoulamoglou, M. Tolia, E. Bournakis, E. Ronne, and V. Barbounis, “Submerged goiter proven to be metastatic infiltration of a neuro-endocrine Merkel cell carcinoma,” SpringerPlus, vol. 3, no. 1, pp. 1–5, 2014. View at: Publisher Site | Google Scholar
  10. G. Aydogdu, D. Ece, D. Yilmazbayhan et al., “Carcinoid tumour metastatic to the thyroid gland diagnosed by fine needle aspiration: a report of 2 cases,” in Proceedings of the 36th European Congress of Cytology, Istanbul, Turkey, September 2011. View at: Google Scholar
  11. N. C. Goldman, C. I. Hood, and G. T. Singleton, “Carcinoid of the larynx,” Archives of Otolaryngology, vol. 90, no. 1, pp. 64–67, 1969. View at: Publisher Site | Google Scholar
  12. A. Machens, H.-J. Holzhausen, and H. Dralle, “Minimally invasive surgery for recurrent neuroendocrine carcinoma of the supraglottic larynx,” European Archives of Oto-Rhino-Laryngology, vol. 256, no. 5, pp. 242–246, 1999. View at: Publisher Site | Google Scholar
  13. F. K. Azar, S. L. Lee, and J. E. Rosen, “Medullary thyroid cancer: an update for surgeons,” The American Surgeon, vol. 81, no. 1, pp. 1–8, 2015. View at: Google Scholar
  14. S. Leboulleux, E. Baudin, J.-P. Travagli, and M. Schlumberger, “Medullary thyroid carcinoma,” Clinical Endocrinology, vol. 61, no. 3, pp. 299–310, 2004. View at: Publisher Site | Google Scholar
  15. M. P. Pusztaszeri, M. Bongiovanni, and W. C. Faquin, “Update on the cytologic and molecular features of medullary thyroid carcinoma,” Advances in Anatomic Pathology, vol. 21, no. 1, pp. 26–33, 2014. View at: Publisher Site | Google Scholar
  16. S. P. A. Toledo, D. M. Lourenço Jr., M. A. Santos, M. R. Tavares, R. A. Toledo, and J. E. D. M. Correia-DeurI, “Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma,” Clinics, vol. 64, no. 7, pp. 699–706, 2009. View at: Publisher Site | Google Scholar
  17. R. S. Sippel, M. Kunnimalaiyaan, and H. Chen, “Current management of medullary thyroid cancer,” The Oncologist, vol. 13, no. 5, pp. 539–547, 2008. View at: Publisher Site | Google Scholar
  18. S. Guyétant, M.-C. Rousselet, M. Durigon et al., “Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 1, pp. 42–47, 1997. View at: Publisher Site | Google Scholar
  19. S. Guyétant, N. Josselin, F. Savagner, V. Rohmer, S. Michalak, and J.-P. Saint-André, “C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients,” Modern Pathology, vol. 16, no. 8, pp. 756–763, 2003. View at: Publisher Site | Google Scholar
  20. G. Nava, K. Greer, J. Patterson, and K. Y. Lin, “Metastatic cutaneous breast carcinoma: a case report and review of the literature,” Canadian Journal of Plastic Surgery, vol. 17, no. 1, pp. 25–27, 2009. View at: Google Scholar
  21. P. R. Dahl, D. G. Brodland, J. R. Goellner, and I. D. Hay, “Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy,” Journal of the American Academy of Dermatology, vol. 36, no. 4, pp. 531–537, 1997. View at: Publisher Site | Google Scholar
  22. A. Ghanadan, “Asynchronous cutaneous metastases of medullary thyroid carcinoma,” South Asian Journal of Cancer, vol. 4, no. 2, pp. 103–104, 2015. View at: Publisher Site | Google Scholar
  23. J. M. Woodruff and R. T. Senie, “Atypical carcinoid tumor of the larynx. A critical review of the literature,” ORL, vol. 53, no. 4, pp. 194–209, 1991. View at: Publisher Site | Google Scholar

Copyright © 2015 Lauren LaBryer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1147 Views | 420 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.